Diffusion-weighted imaging and FDG PET/CT: predicting the prognoses with apparent diffusion coefficient values and maximum standardized uptake values in patients with invasive ductal carcinoma

World Journal of Surgical Oncology

Volumn 10, Issue , 2012, Pages

  Choi, Bo B ^a   Kim, Sung H ^b   Kang, Bong J ^b   Lee, Ji H ^b   Song, Byung J ^b   Jeong, Seung H ^b   Yim, Hyeon W ^b  

^a Chungnam National University College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

breast; diffusion magnetic resonance imaging; Invasive ductal carcinoma; magnetic resonance imaging; positron emission tomography

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84862755442     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-10-126     Document Type: Article

References (27)

1. Nakajo M, Kajiya Y, Kaneko T, Kaneko Y, Takasaki T, Tani A, Ueno M, Koriyama C, Nakajo M. FDG PET/CT and diffusion-weighted imaging for breast cancer: prognostic value of maximum standardized uptake values and apparent diffusion coefficient values of the primary lesion. Eur J Nucl Med Mol Imaging 2010, 37:2011-2020. 10.1007/s00259-010-1529-7, 20607535.
2. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, Shishikura T, Imazeki K, Nakajima N. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro [18 F]-D-glucose. Cancer 1998, 82:2227-2234. 10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO;2-W, 9610703.
3. Ikenaga N, Otomo N, Toyofuku A, Ueda Y, Toyoda K, Hayashi T, Nishikawa K, Tanaka M. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 2007, 73:1151-1157.
4. Kim SH, Cha ES, Kim HS, Kang BJ, Choi JJ, Jung JH, Park YG, Suh YJ. Diffusion-weighted imaging of breast cancer: correlation of the apparent diffusion coefficient value with prognostic factors. J Magn Reson Imaging 2009, 30:615-620. 10.1002/jmri.21884, 19711411.
5. Ho KC, Lin G, Wang JJ, Lai CH, Chang CJ, Yen TC. Correlation of apparent diffusion coefficients measured by 3 T diffusion-weighted MRI and SUV from FDG PET/CT in primary cervical cancer. Eur J Nucl Med Mol Imaging 2009, 36:200-208. 10.1007/s00259-008-0936-5, 18779960.
6. Jeh SK, Kim SH, Kim HS, Kang BJ, Jeong SH, Yim HW, Song BJ. Correlation of the apparent diffusion coefficient value and dynamic magnetic resonance imaging findings with prognostic factors in invasive ductal carcinoma. J Magn Reson Imaging 2011, 33:102-109. 10.1002/jmri.22400, 21182127.
7. Razek AA, Gaballa G, Denewer A, Nada N. Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed 2010, 23:619-623. 10.1002/nbm.1503, 20232453.
8. Hatakenaka M, Soeda H, Yabuuchi H, Matsuo Y, Kamitani T, Oda Y, Tsuneyoshi M, Honda H. Apparent diffusion coefficients of breast tumors: clinical application. Magn Reson Med Sci 2008, 7:23-29. 10.2463/mrms.7.23, 18460845.
9. Kuroki-Suzuki S, Kuroki Y, Nasu K, Nawano S, Moriyama N, Okazaki M. Detecting breast cancer with non contrast MR imaging: combining diffusion-weighted and STIR imaging. Magn Reson Med Sci 2007, 6:21-27. 10.2463/mrms.6.21, 17510539.
10. Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008, 5:220-233.
11. Park SH, Moon WK, Cho N, Chang JM, Im SA, Park IA, Kang KW, Han WS, Noh DY. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol 2012, 22:18-25. 10.1007/s00330-011-2236-x, 21845462.
12. Tsushima Y, Takahashi-Taketomi A, Endo K. Magnetic resonance (MR) differential diagnosis of breast tumors using apparent diffusion coefficient (ADC) on 1.5-T. J Magn Reson Imaging 2009, 30:249-255. 10.1002/jmri.21854, 19629992.
13. Marini C, Iacconi C, Giannelli M, Cilotti A, Moretti M, Bartolozzi C. Qualitative diffusion-weighted MR imaging in the differential diagnosis of breast lesions. Eur Radiol 2007, 17:2646-2655. 10.1007/s00330-007-0621-2, 17356840.
14. Park MJ, Cha ES, Kang BJ, Ihn YK, Baik JH. The role of diffusion-weighted imaging and the apparent diffusion coefficient (ADC) values for breast tumors. Korean J Radiol 2007, 8:390-396. 10.3348/kjr.2007.8.5.390, 2626812, 17923781.
15. Guo Y, Cai Y, Cai Z, Gao YG, An NY, Ma L, Mahankali S, Gao JH. Differentiation of clinically benign and malignant breast lesions using diffusion weighted imaging. J Magn Reson Imaging 2002, 16:172-178. 10.1002/jmri.10140, 12203765.
16. Makkat S, Luypaert R, Stadnik T, Bourgain C, Sourbron S, Dujardin M, De Greve J, De Mey J. Deconvolution-based dynamic contrast-enhanced MR imaging of breast tumors: correlation of tumor blood flow with human epidermal growth factor receptor 2 status and clinicopathologic findings-preliminary results. Radiology 2008, 249:471-482. 10.1148/radiol.2492071147, 18780825.
17. Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast Cancer Res 2004, 6:109-118. 10.1186/bcr777, 400674, 15084231.
18. Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 2000, 60:7094-7098.
19. Ludovini V, Sidoni A, Pistoloa L, Bellezza G, De Angelis V, Gori S, Mosconi AM, Bisagni G, Cherubini R, Bian AR, Rodinò C, Sabbatini R, Mazzocchi B, Bucciarelli E, Tonato M, Colozza M. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stage I and II breast cancer patients. Breast Cancer Res Treat 2003, 81:159-168. 10.1023/A:1025755717912, 14572158.
20. Black R, Prescott R, Bers K, Hawkins A, Stewart H, Forrest P. Tumor cellularity, oestrogen receptors and prognosis in breast cancer. Clin Oncol 1983, 9:311-318.
21. Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, Watanabe M, Hayakawa K. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr 2005, 29:644-649. 10.1097/01.rct.0000171913.74086.1b, 16163035.
22. Yoshikawa MI, Ohsumi S, Sugata S, Kataoka M, Takashima S, Mochizuki T, Ikura H, Imai Y. Relation between cancer cellularity and apparent diffusion coefficient values using diffusion-weighted magnetic resonance imaging in breast cancer. Radiat Med 2008, 26:222-226. 10.1007/s11604-007-0218-3, 18509722.
23. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 1999, 17:2334-2340.
24. Mussurakis S, Buckley DL, Horsman A. Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging. Radiology 1997, 203:317-321.
25. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y, Mochizuki H. Clinicopathological and prognostic relevance of uptake level using 18 F-fluodeoxyglucose positron emission tomography/computed tomography fusion imaging (18 F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 2008, 38:250-258. 10.1093/jjco/hyn019, 18407934.
26. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, Joshi U, Semenza GL, Hoekstra OS, Lammertsma AA, Molthoff CF. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002, 20:379-387. 10.1200/JCO.20.2.379, 11786564.
27. Ito K, Kato T, Ohta T, Tadakoro M, Yamada T, Ikeda M, Masanari N, Ishigaki T, Ito K, Gambhir S. Fluorine-18 fluoro-2-deoxyglucose positron emission tomography in recurrent rectal cancer: relation to tumour size and cellularity. Eur J Nucl Med 1996, 23:1372-1377. 10.1007/BF01367594, 8781143.